1 / 1

Prurigo Nodularis Market

Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution.<br><br>As per the Delveinsight, in 2017, the market size of Prurigo Nodularis in 7MM was USD 659.29 Million.<br><br>The total diagnosed prevalent population of Prurigo Nodularis in 7MM was 539,893 in 2017. Among the 7MM, the United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases. <br><br>Government initiatives, pipeline advancements and various off-label therapies, growth in R&D and increase in the number of patients are the key drivers for Prurigo Nodularis Market.<br><br>The key companies in the Prurigo Nodularis Market includes Menlo Therapeutics, Trevi Therapeutics, Galderma, Amgen, Maruho, Kiniksa Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals and many others.<br><br>Source: Prurigo Nodularis Market<br><br>For more information on Prurigo Nodularis Market, visit:<br>https://www.delveinsight.com/report-store/prurigo-nodularis-market<br><br>

Download Presentation

Prurigo Nodularis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    More Related